Verve Therapeutics
Verve Therapeutics is dedicated to protecting the world from cardiovascular disease through the development of groundbreaking, single-course gene editing medicines. Their mission is to transform treatment paradigms for cardiovascular diseases, including familial hypercholesterolemia and atherosclerotic cardiovascular disease, by leveraging advances in human genetics and gene editing technologies. With a focus on innovative therapies targeting genes such as PCSK9 and ANGPTL3, Verve aims to address unmet medical needs and improve patient outcomes worldwide.
Industries
Nr. of Employees
medium (51-250)
Verve Therapeutics
Products
Clinical-stage base editing candidate targeting PCSK9 (liver-directed)
A liver-directed base editing therapeutic candidate designed to inactivate PCSK9 in hepatocytes to durably lower LDL‑C; being evaluated in clinical studies for familial hypercholesterolemia and related CVD indications.
Clinical-stage base editing candidate targeting ANGPTL3 (liver-directed)
A liver-directed base editing therapeutic candidate designed to inactivate ANGPTL3 to lower LDL‑C and remnant cholesterol; being developed for homozygous familial hypercholesterolemia and refractory hypercholesterolemia.
Clinical-stage base editing candidate targeting PCSK9 (liver-directed)
A liver-directed base editing therapeutic candidate designed to inactivate PCSK9 in hepatocytes to durably lower LDL‑C; being evaluated in clinical studies for familial hypercholesterolemia and related CVD indications.
Clinical-stage base editing candidate targeting ANGPTL3 (liver-directed)
A liver-directed base editing therapeutic candidate designed to inactivate ANGPTL3 to lower LDL‑C and remnant cholesterol; being developed for homozygous familial hypercholesterolemia and refractory hypercholesterolemia.
Services
Clinical trial programs for gene editing candidates
Execution of clinical studies enrolling patients to evaluate safety and activity of in vivo gene editing candidates targeting cardiovascular risk genes.
Strategic collaborations and licensing for gene editing and delivery
Partnering and licensing arrangements to in‑license gene editing and delivery technologies and collaborate on program development.
Clinical trial programs for gene editing candidates
Execution of clinical studies enrolling patients to evaluate safety and activity of in vivo gene editing candidates targeting cardiovascular risk genes.
Strategic collaborations and licensing for gene editing and delivery
Partnering and licensing arrangements to in‑license gene editing and delivery technologies and collaborate on program development.
Expertise Areas
- Gene editing therapeutics
- Base editing
- Liver-targeted therapeutic development
- Cardiovascular disease therapeutics (ASCVD, FH, RH)
Key Technologies
- Base editing
- In vivo somatic gene editing
- Liver-directed delivery
- GalNAc conjugates